Latest filing published 23 Jan 2026 for Edgewise Therapeutics, Inc., €4,552. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Badreddin Edris (senior executive) discloses dealings in 2 companies, chiefly SpringWorks Therapeutics, Inc. and Edgewise Therapeutics, Inc. Over a trading history stretching from 1 July 2021 to 21 January 2026, the count stands at 16 filings.
The open-market record consists of 6 sales worth €5.4M, with no purchase. Other entries cover 8 share grants and 1 option exercise.
The record was last updated on 23 January 2026 with an option exercise (€4,552) in Edgewise Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
16 of 16 declarations